ReviewClinical & experimental metastasis2026
The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction.
Review in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By conducting colorectal cancer liver metastases (CRLM) clinical trials and analyzing treatment and prognostic targets, to provide clinical trial references for CRLM. We analyzed global and Chinese CRLM clinical trials from the Informa database, focusing on fruquintinib, sintilimab, and dual immunotherapy (CTLA-4 + PD-1). The study evaluated oncogenic biomarkers and therapeutic targets, assessing their safety by integrating data from Genotype-Tissue Expression (GTEx)-RNA, Human Protein Atlas (HPA)-RNA and HPA-Protein. Target specificity and future potential were further investigated using Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets and HPA pathology. CRLM clinical trials numbers have stabilized, focusing mainly on combination therapies, with China and the US leading in trial numbers. Single-agent trials emphasize targeted therapy, while chemo plus targeted therapy dominates combinations, reflecting a treatment model based on chemotherapy with targeted therapy breakthroughs. Chinese independently developed drugs-fruquintinib and sintilimab-and dual immunotherapy (CTLA-4 + PD-1) are still emerging, with fruquintinib used for CRLM resistant to multi-line chemo and anti-VEGF. The relevance of VEGFA and EGFR targets highlights targeted therapy's importance and supports drugs like fruquintinib. Targets analysis shows most have low safety and specificity, but CD34, FLT1, and TP53 exhibit good profiles and potential for CRLM therapy and prognosis. This study, by integrating and analyzing the clinical trial data related to CRLM, aims to conduct an in-depth investigation and evaluate the safety specificity of the treatment targets through reference.
Indexed as
Identifiers
41549130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.